Cargando…

Treatment strategies for hepatocellular carcinoma with extrahepatic metastasis

Extrahepatic metastasis (EHM) of hepatocellular carcinoma (HCC) has increasingly been seen due to improved survival with effective management of intrahepatic lesions. The presence of EHM indicates an advanced stage of HCC, for which systemic therapy serves as the standard treatment modality. Since t...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Hai-Yi, Huang, Tong-Yi, Xie, Xiao-Yan, Long, Jian-Ting, Liu, Bao-Xian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316954/
https://www.ncbi.nlm.nih.gov/pubmed/34368295
http://dx.doi.org/10.12998/wjcc.v9.i21.5754
_version_ 1783729975316185088
author Long, Hai-Yi
Huang, Tong-Yi
Xie, Xiao-Yan
Long, Jian-Ting
Liu, Bao-Xian
author_facet Long, Hai-Yi
Huang, Tong-Yi
Xie, Xiao-Yan
Long, Jian-Ting
Liu, Bao-Xian
author_sort Long, Hai-Yi
collection PubMed
description Extrahepatic metastasis (EHM) of hepatocellular carcinoma (HCC) has increasingly been seen due to improved survival with effective management of intrahepatic lesions. The presence of EHM indicates an advanced stage of HCC, for which systemic therapy serves as the standard treatment modality. Since the approval of Sorafenib as the first systemic agent in 2007, it took almost a decade to show its efficacy in both first and further lines of setting until the landscape of systemic drugs was finally expanded. Moreover, with inspiring results from immunotherapy trials in HCC, it appears that the introduction of immunotherapy may lead to an evolution in the portfolio of HCC treatment. Although the locoregional approach in the management of EHM is not recommended for advanced-stage HCC, efforts have been made to demonstrate its efficacy in symptom relief and potential benefit for overall survival. This review provides a summary of recent updates of the systemic agents in the treatment of advanced HCC, with an emphasis on aggressive locoregional management of EHM by various treatment modalities.
format Online
Article
Text
id pubmed-8316954
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-83169542021-08-05 Treatment strategies for hepatocellular carcinoma with extrahepatic metastasis Long, Hai-Yi Huang, Tong-Yi Xie, Xiao-Yan Long, Jian-Ting Liu, Bao-Xian World J Clin Cases Review Extrahepatic metastasis (EHM) of hepatocellular carcinoma (HCC) has increasingly been seen due to improved survival with effective management of intrahepatic lesions. The presence of EHM indicates an advanced stage of HCC, for which systemic therapy serves as the standard treatment modality. Since the approval of Sorafenib as the first systemic agent in 2007, it took almost a decade to show its efficacy in both first and further lines of setting until the landscape of systemic drugs was finally expanded. Moreover, with inspiring results from immunotherapy trials in HCC, it appears that the introduction of immunotherapy may lead to an evolution in the portfolio of HCC treatment. Although the locoregional approach in the management of EHM is not recommended for advanced-stage HCC, efforts have been made to demonstrate its efficacy in symptom relief and potential benefit for overall survival. This review provides a summary of recent updates of the systemic agents in the treatment of advanced HCC, with an emphasis on aggressive locoregional management of EHM by various treatment modalities. Baishideng Publishing Group Inc 2021-07-26 2021-07-26 /pmc/articles/PMC8316954/ /pubmed/34368295 http://dx.doi.org/10.12998/wjcc.v9.i21.5754 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Review
Long, Hai-Yi
Huang, Tong-Yi
Xie, Xiao-Yan
Long, Jian-Ting
Liu, Bao-Xian
Treatment strategies for hepatocellular carcinoma with extrahepatic metastasis
title Treatment strategies for hepatocellular carcinoma with extrahepatic metastasis
title_full Treatment strategies for hepatocellular carcinoma with extrahepatic metastasis
title_fullStr Treatment strategies for hepatocellular carcinoma with extrahepatic metastasis
title_full_unstemmed Treatment strategies for hepatocellular carcinoma with extrahepatic metastasis
title_short Treatment strategies for hepatocellular carcinoma with extrahepatic metastasis
title_sort treatment strategies for hepatocellular carcinoma with extrahepatic metastasis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316954/
https://www.ncbi.nlm.nih.gov/pubmed/34368295
http://dx.doi.org/10.12998/wjcc.v9.i21.5754
work_keys_str_mv AT longhaiyi treatmentstrategiesforhepatocellularcarcinomawithextrahepaticmetastasis
AT huangtongyi treatmentstrategiesforhepatocellularcarcinomawithextrahepaticmetastasis
AT xiexiaoyan treatmentstrategiesforhepatocellularcarcinomawithextrahepaticmetastasis
AT longjianting treatmentstrategiesforhepatocellularcarcinomawithextrahepaticmetastasis
AT liubaoxian treatmentstrategiesforhepatocellularcarcinomawithextrahepaticmetastasis